Related Experiment Videos

[Effect of simvastatin on cardiac fibrosis in patients with essential hypertension]

Guo-Gang Zhang1, Sai-Dan Zhang

  • 1Department of Cardiology, Xiangya Hospital, Central South University, Changsha 410008, China. xyzzgg@sina.com

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|July 28, 2005
PubMed

Insights

Adding simvastatin to benazepril significantly reduced myocardial fibrosis and improved cardiac function in patients with essential hypertension. This combination therapy offers a promising approach for managing cardiac remodeling in hypertensive individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Research

Context:

  • Essential hypertension (EH) is a significant risk factor for cardiovascular complications, including myocardial fibrosis and left ventricular hypertrophy.
  • Current treatments primarily focus on blood pressure control, but addressing the underlying fibrotic processes is crucial for improving long-term outcomes.

Purpose:

  • To investigate the efficacy of simvastatin, in combination with benazepril, an angiotensin-converting enzyme inhibitor, in mitigating myocardial fibrosis and improving cardiac function in patients with essential hypertension.

Summary:

  • A 6-month randomized study compared benazepril alone versus simvastatin plus benazepril in 60 EH patients.
  • Measurements included serum procollagen peptides (PIIIP, PIVP), plasma TGF-β1, and Doppler echocardiographic parameters.
  • The combination group showed significantly greater reductions in TGF-β1 and improved diastolic function (VE/VA ratio) compared to benazepril alone.

Impact:

  • Simvastatin combined with ACE inhibitors effectively reduces myocardial fibrosis and ameliorates left ventricular hypertrophy and diastolic dysfunction in EH patients.
  • This therapeutic strategy may offer a novel approach to target fibrotic pathways and improve cardiac remodeling in hypertension.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...